Physician profile
Kerry Martin
NPI 1063078186
$6,536.48
in general payments reported to CMS, 2019-2025
45 companies · $2,478 in 2025
The $2,478 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $93.39 · 2023: $1,581 · 2024: $2,384 · 2025: $2,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,443.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $757.01 | 2022-2025 | |
| Ucb, INC. | $704.52 | 2023-2025 | Rystiggo, Briviact, Zilbrysq |
| Pfizer INC. | $649.54 | 2023-2025 | |
| Biogen, INC. | $484.14 | 2023-2025 | Tysabri, Vumerity, Avonex |
| Teva Pharmaceuticals USA, INC. | $311.74 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Celgene Corporation | $295.99 | 2023-2025 | Zeposia |
| Argenx US, INC. | $292.88 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $272.21 | 2023-2025 | |
| Genentech USA, INC. | $200.13 | 2023-2025 | Evrysdi, Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $191.80 | 2023-2025 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $172.37 | 2023-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $171.05 | 2023-2025 | Vyepti |
| Lilly USA, LLC | $163.50 | 2023-2025 | Emgality, Amyvid, Kisunla |
| Neurocrine Biosciences, INC. | $162.96 | 2023-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $159.43 | 2024-2025 | Hyqvia |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $147.38 | 2023-2025 | Gamunex-C |
| Eisai INC. | $125.96 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $124.01 | 2024-2025 | Crexont, Ongentys 50mg Capsules 30 |
| Tg Therapeutics, INC. | $103.04 | 2025 | |
| Axsome Therapeutics, INC. | $85.35 | 2025 | Symbravo |
| Acadia Pharmaceuticals INC | $81.65 | 2025 | Nuplazid |
| Kyowa Kirin, INC. | $78.02 | 2022-2024 | Nourianz |
| Genzyme Corporation | $66.36 | 2022-2025 | |
| Mdd US Operations, LLC | $64.50 | 2023-2024 | Gocovri, Gocovri |
| Janssen Biotech, INC. | $63.71 | 2025 | |
| Sk Life Science, INC. | $61.05 | 2023-2024 | |
| Impel Pharmaceuticals INC. | $54.73 | 2023 | Trudhesa |
| Jazz Pharmaceuticals INC. | $52.03 | 2025 | |
| Amgen INC. | $43.27 | 2023-2025 | Aimovig, Uplizna |
| Astrazeneca Pharmaceuticals LP | $39.21 | 2023-2025 | Wainua |
| Acorda Therapeutics, INC | $38.26 | 2023-2024 | Inbrija |
| Mallinckrodt Hospital Products INC. | $34.51 | 2024 | Acthar |
| Merz Pharmaceuticals, LLC | $30.22 | 2024 | Xeomin |
| Alnylam Pharmaceuticals INC. | $28.22 | 2023 | Onpattro |
| Neurelis, INC. | $27.98 | 2023 | Valtoco |
| Aucta Pharmaceuticals, INC. | $24.63 | 2025 | Motpoly Xr |
| Medtronic, INC. | $24.32 | 2024 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $23.82 | 2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $23.32 | 2024 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $18.70 | 2022 | |
| Tris Pharma INC | $18.65 | 2025 | Dyanavel Xr |
| Insightec,INC | $17.92 | 2025 | Exablate |
| Upsher-Smith Laboratories LLC | $15.93 | 2022 | |
| Inspire Medical Systems, INC. | $15.41 | 2025 | Inspire |
| Scilex Pharmaceuticals INC. | $15.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.